
07/23/2025
It was hard enough the first time Conor was diagnosed with synovial sarcoma, a rare soft tissue cancer, at age 17.
Then three years after finishing treatment, early in his senior year of college, came the devastating news: His synovial sarcoma was back, and it had spread to his lungs, making it stage 4.
“I just kind of shut down when I found out,” he says. “I was in so much shock.” His parents acted quickly and decided he needed to go to MSK. He met with sarcoma medical oncologist Dr. Sandra D’Angelo, who offered him a treatment being investigated in a clinical trial: afami-cel, a T cell receptor therapy that trains the immune system to recognize and attack cancer.
“Dr. D’Angelo was very confident that this was a good option for me, and it really put my parents and I at ease,” Conor remembers. Even better, Dr. D’Angelo arranged Conor's treatment around his schedule, so he wouldn’t miss any classes.
Conor received his treatment over winter break, beginning with chemotherapy to prepare his body for the engineered T cells. After the infusion, he recovered quickly and within a week, he was home. A month later, Conor's scans showed that his tumors stopped growing.
“My family and I were amazed and very grateful,” he says. “I was able to resume normal life very quickly.” Not only did he finish his last semester of college, Conor also rejoined his school’s Division 1 golf team.
Now 23 and 18 months out from treatment, Conor says he feels great and is living a full life — playing golf, working full time as a project analyst, and hanging out with his friends.
Leave a 👏 in the comments for Conor and learn how MSK is advancing care for rare cancers like synovial sarcoma: https://bit.ly/3H0i5wn